---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-002704"
form_type: "8-K"
ticker: "SPRB"
cik: "0001683553"
company_name: "SPRUCE BIOSCIENCES, INC."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:22:48.257218+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Spruce Biosciences provides cash update; adult CAH trials enrollment complete; topline data expected March 2024

## Summary
- Cash and equivalents ~$96M as of Dec 31, 2023; 41.0M shares outstanding.
- CAHmelia-203 (N=96) and CAHptain-205 (N=30) enrollment complete, surpassing targets.
- CAHmelia-204 enrollment to finish Jan 2024 (N~98); topline results from CAHmelia-203 and CAHptain-205 expected March 2024.
- Baseline characteristics: CAHmelia-203 mean A4 1,149 ng/dL on 27 mg/day GC; CAHmelia-204 mean A4 214 ng/dL on 35 mg/day GC.
- Cash runway into first half of 2025.

## SEC filing metadata
- accession: 0000950170-24-002704
- form_type: 8-K
- ticker: SPRB
- cik: 0001683553
- company_name: SPRUCE BIOSCIENCES, INC.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01, 7.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1683553/000095017024002704/0000950170-24-002704-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1683553/000095017024002704/sprb-20240104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-002704
- JSON: https://secwatch.observer/filing/0000950170-24-002704.json
- Plain text: https://secwatch.observer/filing/0000950170-24-002704.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.